MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
PCSA - Processa Pharmaceuticals Inc
$10.82
-0.90(-7.68%)8:59:57 PM 2/25/2021
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • MACD is crossing MACD signal line at 0.4. MACD crossing signal line is bullish signal.
Stock Statistics
MarketCap123.4M
PE Ratio
PEG Ratio
P/B7.0
P/S (ttm)
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %0%
Held by Institutions %11%
1 Day Vol Adjusted Return-0.8
1 Month Vol Adjusted Return7.7
3 Month Vol Adjusted Return13.7
6 Month Vol Adjusted Return
20 Days SMA Price ZScore1.1
50 Days SMA Price ZScore2.0
12 -26 Days PPO14.2
1 Month Average Short Volume Ratio37.2
1 Day Volume Change ZScore-0.1
1 Month Daily Vol9.1
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/22/2021PCSA
    Encode Ideas, L.P. Announces the Initiation of Research Coverage on Processa Pharmaceuticals, Inc.

    Dover, Delaware--(Newsfile Corp. - February 22, 2021) - Encode Ideas, L.P. Initiates Research on Processa Pharmaceuticals, Inc. (NASDAQ: PCSA). The full research publication is available here and available on our website at www.encodelp.com. Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on Processa Pharmaceuticals, Inc. (NASDAQ: PCSA). The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with u...

    02/19/2021PCSA
    Do Institutions Own Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares?

    The big shareholder groups in Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ) have power over the company. Large...

    02/17/2021PCSA
    Processa Pharmaceuticals Announces $10.2 Million Strategic Financing

    Strengthened Financial Position Supports Execution Through 2023 HANOVER, MD., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that it has executed a securities purchase agreement to raise gross proceeds of $10.2 million resulting from the sale of 1,321,132 shares thr...

    01/11/2021PCSA
    Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

    HANOVER, MD., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The presentation is now available for on-demand listening by visiting https://hcwevents.com/bioconnect/. The press r...

    11/16/2020PCSA
    Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

    Processa’s pipeline includes several clinical-stage drug candidatesHANOVER, MD., Nov. 16, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences:Craig-Hallum Alpha Select Virtual Conference * T...

    11/12/2020PCSA
    Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update

    Highlights include closing $19.2 million public offering, uplisting to Nasdaq, and positive progress with multiple candidates currently in Processa’s clinical drug pipelineHANOVER, MD., Nov. 12, 2020 (GLOBE NEWSWIRE) -- via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life for p...

    11/5/2020PCSA
    Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors

    HANOVER, MD, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, is pleased to announce the appointment of Dr. Khalid Islam to its board of directors. “I’d like to personally welcome Dr. Islam to the board,” commented Dr. David Young, Chairman and CEO of Processa Pharmaceuticals....